News | Radiation Therapy | February 10, 2016

New Study Finds Interruption of Radiation Therapy Risks Cancer Recurrence

Missing two radiotherapy appointments may impair tumor control, particularly for head and neck cancers

radiation therapy, missing appointments, cancer recurrence, Montefiore Medical Center

February 10, 2016 — Cancer patients who miss two or more radiation therapy sessions have a worse outcome than fully compliant patients, investigators in a new study have found.

The study was conducted by investigators at Montefiore Einsten Center for Cancer Care and Albert Einstein College of Medicine’s NCI-designated Albert Einstein Cancer Center. It was published in the International Journal of Radiation Oncology Biology Physics.

The results suggest that this noncompliance to scheduled treatments may represent a new behavioral biomarker for identifying high-risk patients who require additional interventions to achieve optimal care outcomes.

The study evaluated 1,227 patients scheduled for courses of external beam radiation therapy for cancers of the head and neck, breast, lung, cervix uterus or rectum from 2007 to 2012. Two hundred twenty-six of these patients (22 percent) were noncompliant (i.e., they missed two or more scheduled radiation therapy appointments). All patients eventually completed the radiation therapy course planned for them.

The radiation therapy course for noncompliant patients was prolonged for an average of one week compared with compliant patients. Nevertheless, 16 percent of noncompliant patients later experienced a recurrence of their cancers versus only a 7 percent recurrence rate for compliant patients.

“This study shows that the health of our patients can improve only when a course of treatment is completed in the prescribed period of time,” said Madhur Garg, M.D., clinical director, Department of Radiation Oncology, MECCC and professor of clinical radiation oncology at Einstein. “These findings should serve as a wakeup call to physicians, patients and their caregivers about the critical need to adhere to a recommended treatment schedule.”

Prolonging radiation therapy for head and neck cancer or cervical cancer impacted tumor control and overall survival at the greatest rate, at 1 percent per day, however this negative impact was seen in all cancers studied. This is attributed to tumor repopulation, which can accelerate after treatment initiation.

“We previously conducted a study that demonstrated a statistically significant relationship between lower socioeconomic status and non-compliance,” said Nitin Ohri, M.D., attending physician, MECCC and assistant professor of radiation oncology at Einstein. “A Multivariable Cox proportional hazard model was informed by this prior study and helped us adjust for demographic variables like age, race, ethnicity and socioeconomic status.”

As an outcome result of this study, management of mood disorders, patient navigator programs and increasing assistance with transportation are being evaluated at Montefiore as interventions that might improve patient care outcomes and close disparities among vulnerable populations.

For more information: www.redjournal.org

Related Content

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017
News | Radiation Therapy | September 19, 2017
Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition...
Elekta to Highlight MOSAIQ Oncology Analytics at ASTRO Annual Meeting
News | Radiation Therapy | September 19, 2017
September 19, 2017 — Elekta will highlight its Mosaiq Oncology...
Theraclion to Launch Metastatic Breast Cancer Trial Combining Echotherapy and Immunotherapy
News | Focused Ultrasound Therapy | September 18, 2017
September 18, 2017 — Theraclion and co-lead investigator David Brenin, M.D., from the University of Virginia School o
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Clinical Trials and Cutting-Edge Radiation Oncology Research to Be Featured at ASTRO 2017
News | Radiation Therapy | September 14, 2017
The program for the 2017 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 24-27 in San...
Blue Earth Diagnostics Announcing Results of FALCON PET/CT Trial at ASTRO 2017
News | PET-CT | September 13, 2017
September 13, 2017 — Blue Earth Diagnostics announced the upcoming oral presentation of initial results from the FALC
Provision Healthcare Joins RayCare Clinical Partners
News | Oncology Information Management Systems (OIMS) | September 11, 2017
Provision, located in Knoxville, Tenn., is the latest to partner with RaySearch Laboratories on the development of its...
U.K.'s NICE Supports Use of Hydrogel Spacer in Prostate Cancer Treatement
News | Patient Positioning Radiation Therapy | September 08, 2017
Augmenix Inc. announced that the National Institute for Health and Care Excellence (NICE) in the U.K. has issued...
Delphinus Enrolls First Patient in Discover Breast Ultrasound Clinical Project
News | Ultrasound Womens Healthcare | September 08, 2017
September 8, 2017 — Delphinus Medical Technologies Inc.
Overlay Init